Trial Profile
A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2012
Price :
$35
*
At a glance
- Drugs Choline fenofibrate (Primary) ; Rosuvastatin (Primary)
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- 04 Oct 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 09 Jun 2011 Actual initiation date (Jun 2008) added as reported by ClinicalTrials.gov.
- 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.